AKAR, S. Et Al. 2018. The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients. EULAR- Annual European Congress of Rheumatology, 2018 , (Amsterdam, Netherlands), 1012.

AKAR, S., KİRAZ, S., GERÇİK, Ö., ERTENLİ, A. İ., KÜÇÜKŞAHİN, O., DALKILIÇ, H. E., ... BES, C.(2018). The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients . EULAR- Annual European Congress of Rheumatology, 2018 (pp.1012). Amsterdam, Netherlands

AKAR, SERVET Et Al. "The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients," EULAR- Annual European Congress of Rheumatology, 2018, Amsterdam, Netherlands, 2018

AKAR, SERVET Et Al. "The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients." EULAR- Annual European Congress of Rheumatology, 2018 , Amsterdam, Netherlands, pp.1012, 2018

AKAR, S. Et Al. (2018) . "The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients." EULAR- Annual European Congress of Rheumatology, 2018 , Amsterdam, Netherlands, p.1012.

@conferencepaper{conferencepaper, author={SERVET AKAR Et Al. }, title={The role of baseline concomitant use of conventional synthetic disease modifying anti-rheumatic drugs with tnf inhibitors in spondyloarthritis patients}, congress name={EULAR- Annual European Congress of Rheumatology, 2018}, city={Amsterdam}, country={Netherlands}, year={2018}, pages={1012} }